Editas collaborates with Bluerock to develop off-the-shelf cell therapiesPublished: April 4, 2019
Cambridge, MA-based gene editing company Editas Medicine has entered into a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to develop and manufacture novel engineered off-the-shelf cell therapies.
The collaboration will work to create novel allogeneic pluripotent stem cell (PSC) lines by combining Editas Medicine’s CRISPR genome editing technology and BlueRock’s induced pluripotent stem cell (iPSC) platform.
The cross-licensing deal will allow each company to gain non-exclusive rights to the other’s technology, with Bluerock focusing on neurology, cardiology and immunology and Editas working on cancer treatments. BlueRock will have access to Editas’ CRISPR technology and Editas to BlueRock’s cell differentiation technology.
By combining these two technologies, the companies believe that they would be able to create powerful off-the-shelf engineered cell therapies that could transform regenerative medicine.
Under the terms of the agreement, each company will pay development, regulatory and commercial milestones to the other for any engineered cell therapy developed in their respective field as well as royalties on global net product sales.
This agreement comes two months after Editas’ former CEO Katrine Bosley stepped down from her role following the exits of CMO Gerald Cox and CFO Andrew Hack. Cynthia Collins is Editas’ interim CEO.
Dr Emile Nuwaysir, BlueRock’s CEO commented: “BlueRock and Editas share a common belief in the disruptive potential of utilizing an engineered cell as a therapeutic. We are equally committed and passionate about bringing these new treatment options to those living with diseases where the unmet medical need is high and growing. We are thrilled to partner with the world-class scientific team at Editas and believe that this new collaboration will allow both companies to meaningfully expand our pipelines in a manner that further positions both as leaders in our respective fields.”
Source: Editas, BlueRock team up to develop off-the-shelf engineered cell therapies; Press Release